Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst
Scribe Surges On IPO Debut -- But All Eyes Turn To 1H27 Data
HC Wainwright & Co. Reiterates Buy on Scribe Therapeutics, Maintains $60 Price Target
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Scribe Therapeutics Q3 EPS $(2.62) Misses $(1.05) Estimate, Sales $1.918M Miss $3.113M Estimate
Scribe Therapeutics to Participate in Upcoming Investor Conferences
HC Wainwright & Co. Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $60
Wells Fargo Initiates Coverage On Scribe Therapeutics with Overweight Rating, Announces Price Target of $60
Leerink Partners Initiates Coverage On Scribe Therapeutics with Outperform Rating, Announces Price Target of $37
Guggenheim Initiates Coverage On Scribe Therapeutics with Buy Rating, Announces Price Target of $50
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
Scribe Therapeutics Starts IPO Effort For CRISPR Pipeline Development
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
